Ahmed, Hossain Gias, Uddin Ahsan Hayatun, Nabi
Published in
Advances in Modern Oncology Research
Treatment with chemotherapy is important in limiting the intensity of serous epithelial ovarian cancer. However, not all patients are sensitive to platinum chemotherapy corresponding to longer progression-free survival (PFS >8 months). Koti et al.[1] revealed a set of 204 discriminating genes possessing expression levels, which could influence diff...
Ines, Vasconcelos Oscar, Gaspar
Published in
Advances in Modern Oncology Research
Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most promising drugs for ovarian cancer treatment. This study investigated clinical trials of PARP inhibitors, in order to obtain a more complete prognosis of ovarian cancer patients, which is usually dependent on their BRCA1/2 mutation status. The PubMed database was searched using the k...
Nicolae, Bacalbasa Olivia, Ionescu Paris, Ionescu Irina, Balescu
Published in
Advances in Modern Oncology Research
The standard frontline treatment for advanced-stage ovarian cancer (ASOC) consists of maximal cytoreduction surgery associated with platinum/paclitaxel-based chemotherapy. Several studies have proven that patients with no gross residual disease (RD) have better survival rates than those with optimal but visible RD (RD ≤1 cm). In order to achieve th...
Joanna, Lim S, . Y . Lau N, . S . Ahmad Bashah K, . N . Lai W, . X . Wen D, . J . Park B, . J . Pope T, . Nguyen - Dumont M, . C . Southey L, . K . Wah
...
Published in
Advances in Modern Oncology Research
Background: Germline BRCA1 or BRCA2 pathogenic variants in ovarian cancer patients may be predictive of sensitivity to platinum derivatives and PARP enzyme inhibitors. Population studies have indicated a >10% prevalence of BRCA1/2 pathogenic variants with wide variance amongst ethnically different populations. We aim to establish the first populati...
Wong, Kwong - Kwok
Published in
Advances in Modern Oncology Research
The protein poly (ADP-ribose) polymerase (PARP) plays an important role in DNA base excision repair and repair of DNA single-strand breaks[1] and might also be involved in DNA double-strand break repair[2]. For tumor cells with homologous recombination deficiency (HRD), such as ovarian cancer cells with BRCA1/2 mutations, interfering with PARP acti...
Nor, Syuhada Ahmad Bashah Yin, Leng Woo Joanna, Lim Meow, Keong Thong Soo, Hwang Teo Ma, Gi C Investigators Sook, Yee Yoon
Published in
Advances in Modern Oncology Research
Introduction: Identifying germline BRCA mutations in ovarian cancer patients is important in the medical management of affected patients and for their relatives who can take appropriate action to manage their risk. However, in Malaysia and most of Asia, access to genetic counselling and genetic testing are limited. Few studies on the prevalence of ...
Rotmensch, Jacob Atcher, Robert W. Hines, John Grdina, David Schwartz, Jeffrey S. Toohill, Margaret Herbst, Arthur L.
Published in
American Journal of Obstetrics and Gynecology
α-Emitting radionuclides may be an effective alternative treatment against ovarian carcinoma because they have short half-lives and are densely ionizing, with high linear energy transfer to a depth of several cell diameters without requiring cellular oxygenation. One radionuclide that has been generated and tested in our laboratory in vitro and in ...
Petru, Edgar Tamussino, Karl Lahousen, Manfred Winter, Raimund Pickel, Hellmuth Haas, Josef
Published in
American Journal of Obstetrics and Gynecology
To determine the incidence and clinical import of lymphocysts after radical gynecologic surgery including lymphadenectomy, we reviewed the records of 173 patients with cervical cancer and 135 patients with ovarian cancer who were followed up by computed tomography. Lymphocysts were found in 35 (20%) and 43 (32%) of the patients, respectively. Patie...
Muto, Michael G. Lepisto, Eva M. Van den Abbeele, Annick D. Knapp, Robert C. Kassis, Amin I.
Published in
American Journal of Obstetrics and Gynecology
Human antimurine antibody responses interfere with CA 125 antigen determinations by crosslinking the murine antiovarian carcinoma monoclonal antibody OC 125 with the second murine radiolabeled antibody used in the CA 125 radioimmunoassay. Serial CA 125 levels in 22 patients with epithelial ovarian carcinoma undergoing either radioimmunotherapy or r...
Rubin, Stephen C. Hoskins, William J. Hakes, Thomas B. Markman, Maurie Reichman, Bonnie S. Chapman, Douglas Lewis, John L. Jr.
Published in
American Journal of Obstetrics and Gynecology
Serum CA 125 levels and surgical findings were prospectively compared in 96 secondary laparotomies performed on patients with epithelial ovarian cancer. All patients had documentation of an elevated CA 125 level (>35 U/ml) at a time when ovarian cancer was present, and thus the tumors were known to be “marker positive.” Operation was performed in 4...
